Notably, EPHA2 upregulation is associated with an increased risk for malignancy and a poor clinical prognosis in various cancer types [42,43,44,45,46,47], and EPHB4 expression is widely observed in neoplastic cells, correlating with tumor progression [48,49,50]. This evidence concerns the gene EPHA2 and cancer.